Nkarta, Inc.
NASDAQ:NKTXBiotechnology
+$0.09 today
- Market cap
- $82.37M
- Beta
- 0.90
- P/E (TTM)
- -2.0
- EPS (TTM)
- -$1.35
Volume 0.81M
Average 0.75M
NKTX Other Current Liabilities
Short-term obligations not reported separately, such as accrued expenses.
Nkarta, Inc.NASDAQ: NKTX
Other Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Other current liabilities falls 51.3% from a year ago
Other current liabilities stood at $2.98M at the end of Q1 FY2026, down 51.3% from a year earlier and down 50.9% from the prior quarter. Over 3 fiscal years it compounded at -13.4% a year.
Context
- Other current liabilities amounted to 0.8% of total assets at the end of Q1 FY2026, down 0.5 pp from a year earlier.
- Other current liabilities increased in 1 of the last 3 fiscal years.
What to watch
Whether other current liabilities keeps falling in the next quarterly balance sheet after a -51.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 6.07M USD
- Year-over-year change
- +2287.8%
- 4-year CAGR
- +181.9%
| Period | Period end | Other Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 6.07M | +2287.8% |
| FY2024 | 2024-12-31 | 254K | -96.2% |
| FY2023 | 2023-12-31 | 6.72M | -28.1% |
| FY2022 | 2022-12-31 | 9.35M | +9634.4% |
| FY2021 | 2021-12-31 | 96K | — |
Other Current Liabilities vs competitors
How NKTX compares with its peers on the latest reported figures
- Peers report in different currencies, so other current liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -51.3% is the 6th highest of 7, against a peer median of -27.5%.
- Other current liabilities amounts to 0.8% of total assets for NKTX, versus a peer median of 0.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $8.45M USD | -29.8% | -40.5% | 3.0% | |
ELTXElicio Therapeutics, Inc. | Mar 2026 | $5.92M USD | +329.2% | +78.6% | 26.1% |
| Mar 2026 | $2.98M USD | -51.3% | -13.4% | 0.8% | |
| Mar 2026 | $2.92M USD | +36.3% | +45.8% | 0.6% | |
| Mar 2026 | $1.43M USD | -25.2% | +24.1% | 0.9% | |
| Mar 2026 | $878K USD | -29.8% | +36.2% | 1.3% | |
| Mar 2026 | $0 USD | -100.0% | +24.1% | 0.0% | |
| Mar 2026 | -CHF 20.53K CHF | — | — | 0.0% | |
| Peer median (excluding NKTX) | — | -27.5% | +30.2% | 0.9% | |
Competitors are the stored peer set for NKTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 60.82M | 37.49M | 31.04M | 27.87M | 39.63M |
| Short-term Investments | 177.27M | 314.65M | 217.15M | 239.48M | 236.65M |
| Net Receivables | 0 | 1.3M | 200K | 200K | 2M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 3.15M | 1.63M | 1.42M | 2.54M | 414K |
| Total Current Assets | 245.78M | 360.69M | 253.07M | 273.34M | 282.51M |
| Property, Plant & Equipment (Net) | 24.53M | 107.66M | 119.28M | 110.67M | 101.15M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 2.74M | 2.74M | 110.39M | 16.11M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 3.59M | 1.85M | 3.8M | 6.8M | 4.44M |
| Total Non-current Assets | 28.12M | 112.25M | 125.81M | 227.87M | 121.7M |
| Total Assets | 273.9M | 472.94M | 378.89M | 501.2M | 404.21M |
| Account Payables | 1.11M | 1.76M | 3.67M | 638K | 2.09M |
| Short-term Debt | 0 | 4.25M | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 96K | 9.35M | 6.72M | 254K | 6.07M |
| Total Current Liabilities | 12.94M | 22.05M | 23.33M | 18.92M | 22.27M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 18K | 0 | 0 | 87K | 87K |
| Total Non-current Liabilities | 9.99M | 78.69M | 82.27M | 74.31M | 69.62M |
| Total Liabilities | 22.94M | 100.73M | 105.6M | 93.23M | 91.88M |
| Common Stock | 3K | 5K | 5K | 7K | 7K |
| Retained Earnings | (204.1M) | (317.93M) | (435.43M) | (544.22M) | (648.31M) |
| Accumulated OCI | (150K) | (679K) | 8K | 674K | 407K |
| Other Stockholders Equity | (0) | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 250.97M | 372.21M | 273.29M | 407.98M | 312.33M |
| Total Debt | 12.46M | 82.93M | 88.34M | 80.27M | 76.42M |
| Net Debt | (48.36M) | 45.44M | 57.3M | 52.4M | 36.79M |
Nkarta, Inc.
NASDAQ:NKTX
Intrinsic Alpha fair value
Locked
Current Price
$1.15
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.